Novato, Ca., USA - January 8, 2015, Novato, Ca., USA - Raptor Pharmaceutical Corp., a biopharmaceutical company, appoints Krishna R. Polu as its chief medical officer and Michael P. Smith as CFO, effective January 12, 2015.
Article continues below
Dr. Polu will oversee all global clinical development programs, medical affairs and other related functions. Dr. Polu most recently served as Chief Medical Officer at CytomX Therapeutics, a privately-held biotechnology company focused on the development of Probody therapeutics, a novel monoclonal antibody platform for the treatment of cancer.
Prior to that, he served as Vice President of Clinical Development at Affymax, where he led multiple functions, including clinical sciences, clinical operations and drug safety/pharmacovigilance and was integral to the development and regulatory approval of the company's first drug, OMONTYS, a pegylated peptide for the treatment of anemia due to chronic kidney disease.
Prior to Affymax, he served as Executive Director of Global Development at Amgen and led late-stage clinical research programs across a wide range of therapeutic areas including nephrology, diabetes and heart failure and executed on several large cardiovascular outcomes trials as well as led the global clinical activities to support commercialization for EPOGEN and Aranesp.
Dr. Polu received his B.A. from Stanford University and his M.D. from the University of Texas, San Antonio. In addition, he completed an internal medicine internship and residency at the University of Colorado as well as clinical and research fellowships in nephrology and transplant at Harvard Medical School in a joint program with Brigham and Women's Hospital and Massachusetts General Hospital.
Mr. Smith will serve as Raptor's principal financial and accounting officer. Mr. Smith most recently served as Catalyst Biosciences' Chief Financial and Business Advisor.
Prior to that, he was Vice President of Business Development at iPierian and Chief Financial Officer for Memory Pharmaceuticals where he oversaw all finance, business development, strategic planning, intellectual property and site operation activities.
Previously, he was Vice President of Business Development at QLT. At Chiron, he held several positions of increasing responsibility and also established Chiron's TOBI franchise for cystic fibrosis. Throughout his career, he has managed and led numerous successful financings and corporate and product acquisitions, as well as strategic partnerships. ■